1. Introduction {#s0005}
===============

The development of recombinant subunit vaccines for the protection of small ruminants against parasitic nematodes has been, until recently, relatively unsuccessful ([@b0040], [@b0070], [@b0115]). We developed a rational approach to selecting antigens for inclusion in a vaccine to control *Teladorsagia circumcincta*, the primary cause of parasitic gastroenteritis (PGE) in small ruminants in temperate regions worldwide ([@b0060]). First, given previous understanding of protective immune mechanisms against this parasite ([@b0085], [@b0090], [@b0095], [@b0110]), we selected four proteins by examining larval antigens that were targets of local IgA responses in sheep rendered immune to re-infection. Second, via in silico analysis of stage-specific transcripts of *T. circumcincta*, we selected an immunogenic homologue of a protective antigen of the canine hookworm, *Ancylostoma caninum* (see [@b0050]). Finally, we identified three potentially immunosuppressive molecules released by intra-host larval stages ([@b0060]). We combined these eight antigens in a cocktail to assess whether this vaccine would induce protection against parasite challenge when administered to 6--7 month old lambs in two separate trials. In these studies, this prototype reduced cumulative faecal egg output on average by 70% and 58%, respectively, over a 6 or 10 week period after challenge ([@b0060]). During the period of peak worm egg shedding, vaccinated lambs shed 92% and 73% fewer eggs than did Quil A adjuvant-only recipient lambs, respectively. At post-mortem, vaccinates had 75% and 56% lower mean adult nematode burdens than adjuvant only controls, respectively ([@b0060]). In a subsequent experiment in lambing ewes, which displayed a periparturient relaxation in immunity, vaccination with this eight-protein cocktail resulted in a 44% reduction in mean cumulative faecal egg count (cFEC) levels in recipient ewes compared with adjuvant only control animals ([@b0065]). The vaccine prototype used in these experiments comprised eight proteins expressed separately in *Escherichia coli* or *Pichia pastoris* systems. The complexity of the expression and purification steps made this vaccine unattractive for commercial exploitation, particularly considering current anthelmintic treatment options which, in most cases, are relatively inexpensive ([@b0020]). Here, we explored the previous trial data gathered over 7 years from two previously published (Trials 1 and 2) and three unpublished (Trials 3--5) trials using the eight-protein vaccine to inform a strategy to simplify this vaccine. Based on this analysis, two two-component prototypes were tested in a direct comparison with the original eight-protein vaccine (Trial 6). The simplification strategy was guided by relationships between antigen-specific antibody levels, avidity measurements and parasitological parameters of efficacy analysed for each of the eight proteins in the previous trials and this led to the testing of a vaccine comprising *T. circumcincta* apyrase-1 (Tci-APY-1) and *T. circumcincta* metalloproteinase-1 (Tci-MEP-1). We also tested Tci-MEP-1 in combination with a mutated version of the apyrase, abolishing its enzyme activity and potential immunomodulatory capacity through site directed mutagenesis ([@b0025]), to ablate any possible negative effect on vaccine efficacy.

2. Materials and methods {#s0010}
========================

2.1. Ethics statement {#s0015}
---------------------

All experimental procedures described here were approved by the Moredun Research Institute Experiments and Ethics Committee, UK, and were conducted under the legislation of UK Home Office Project Licenses (references PPL 60/4238 and 70/8870) in accordance with the Animals (Scientific Procedures) Act of 1986.

2.2. Animals {#s0020}
------------

Texel crossbred lambs, reared under conditions to exclude helminth infection (confirmed by FEC analysis), were grouped in separate pens in all trials. Ages and characteristics of the animals are shown in [Table 1](#t0005){ref-type="table"}. In Trial 4, two different ages of lambs were used; 3 month old and 6 month old lambs. Here, all animals were derived from the same lambing, with the trial in 6 month old lambs (Trial 4b) performed 3 months after the trial comprising the 3 month old lambs (Trial 4a).Table 1Characteristics of the animals and experimental groups in each of the trials described.TrialAverage age of lambs at first vaccination (months)Number of lambs in each experimental groupVaccine(s) received177Group 1: 8-antigen vaccine\
Group 2: Adjuvant only2614[a](#tblfn1){ref-type="table-fn"}Group 1: 8-antigen vaccine\
Group 2: Adjuvant only3512Group 1: 8-antigen vaccine\
Group 2: Adjuvant only4a316[b](#tblfn2){ref-type="table-fn"}Group 1: 8-antigen vaccine\
Group 2: Adjuvant only4b616[b](#tblfn2){ref-type="table-fn"}Group 1: 8-antigen vaccine\
Group 2: Adjuvant only5612Group 1: 8-antigen vaccine\
Group 2: Adjuvant only6610[b](#tblfn2){ref-type="table-fn"}Group 1: 8-antigen vaccine\
Group 2: Adjuvant only\
Group 3: Tci-APY-1 plus Tci-MEP-1\
Group 4: mTci-APY-1 plus Tci-MEP-1[^2][^3]

2.3. Recombinant protein production for vaccines {#s0025}
------------------------------------------------

The eight-antigen prototype vaccine used in Trials 1--6 was produced and formulated exactly as described previously ([@b0060]). To produce Tci-APY-1 and mTci-APY-1 for Trial 6, oligonucleotide primers were designed to exclude the first 42 nucleotide bases of the open reading frame (ORF, NCBI Accession number FR671368) encoding the putative signal peptide and the remaining ORF was amplified by PCR and sub-cloned into the expression vector pET-11a (Novagen USA). Site directed mutagenesis was used to replace the nucleotide-binding residue D^118^ with N^118^ for the production of mTci-APY-1. Expression vector pET-11a containing an insert encoding either Tci-APY-1 or mTci-APY-1 was used to transform *E. coli* BL21 (DE3) competent cells (Stratagene USA). Recombinant protein expression was induced in the presence of 1 mM isopropyl β-D-1-thiogalactopyranoside. Soluble Tci-APY-1 or mTci-APY-1 was purified from cell lysate by nickel column affinity chromatography using HisTrap™ HP columns (GE Healthcare UK). Recombinant Tci-APY-1 or mTci-APY-1 was eluted in 350 mM imidazole and dialysed overnight against Tris buffer (50 mM Tris, 0.5 M NaCl, pH 7.4) at 4 °C. Apyrase activity of Tci-APY-1 and lack of activity of mTci-APY-1 was confirmed by monitoring inorganic phosphate release from soluble nucleotides using the malachite green assay as described previously ([@b0055]). Tci-MEP-1 for Trial 6 was produced as described previously ([@b0060]).

2.4. Efficacy trials of experimental vaccines {#s0030}
---------------------------------------------

Six vaccine trials are described here. The protocols and procedures for Trials 1 and 2 have been published ([@b0060]) and these were repeated in Trials 3--5 (any small amendments to the protocol are detailed in [Table 1](#t0005){ref-type="table"}). Briefly, 50 µg of each of the seven PBS-soluble proteins (Tci-ASP-1; Tci-MIF-1; Tci-TGH-2; Tci-APY-1; Tci-SAA-1; Tci-CF-1 and Tci-ES20) were administered to lambs as a mixture in a single injection with 5 mg of Quil A in PBS. Tci-MEP-1, which is insoluble in PBS, was formulated with 2 M urea in PBS plus 5 mg of Quil A and the preparations of seven soluble proteins or one insoluble protein (Tci-MEP-1) were injected separately, one immediately following the other, at two sites on the neck. Three immunisations were administered, 3 weeks apart (2 weeks apart in Trial 5 for logistical reasons). Lambs in all control groups received three immunisations with urea/PBS/10 mg of Quil A at the same time as the lambs immunised with the recombinant proteins. In Trial 6, as well as a group of lambs immunised with all eight recombinant proteins, two additional groups were immunised with the two proteins selected from the original cocktail; Tci-APY-1 plus Tci-MEP-1 in one group and mTci-APY-1 plus Tci-MEP-1 in a second group. Each recombinant protein was formulated as individual injections with 5 mg of Quil A and three immunisations administered 3 weeks apart as described above. In all trials, following the final immunisation, each lamb was administered orally with 2,000 *T. circumcincta* L3s, three times per week for 4 weeks. FEC analysis was performed three times per week in Trials 1--5 or two times per week in Trial 6 from 14 days after the start of the larval challenge period until the end of the experiment. cFEC values were estimated using the trapezoidal method for calculation ([@b0120]). The percentage reduction in cFEC afforded by vaccination was calculated as follows:$$\%\,\text{cFEC}\,\text{reduction}\, = \,\left\lbrack {1 - \left( {\text{cFECv}/\text{mean}\,\text{cFECc}} \right)} \right\rbrack \times 100$$where cFECv = cFEC for an individual vaccinated animal in that trial and cFECc = mean cFEC for the control animals in the same trial.

Abomasal nematode burdens were classified and enumerated following standard techniques ([@b0035]).

2.5. Antibody level and avidity analyses {#s0035}
----------------------------------------

Blood samples were taken from every lamb prior to each immunisation and periodically from the third immunisation onwards. Abomasal swab samples were collected from every lamb at post-mortem. ELISA was performed to determine levels of antigen-specific IgA and IgG in sera and abomasal mucus as described previously ([@b0060], [@b0065]). Serum IgG, IgG1 and IgG2 avidity specific for each vaccine antigen was also assessed in all animals immunised with the eight-antigen prototype (Group 1 in each trial) in samples collected 2--3 weeks after the final (third) immunisation. Antibody avidity was determined in sera from each animal using a standard ELISA as described previously ([@b0060], [@b0070], [@b0065]), with an additional potassium thiocyanate elution step as described by [@b0075]. Briefly, after antigen/sera incubation, microtiter plates were washed six times in PBST (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na~2~HPO~4~, 1.5 mM KH~2~PO~4~, 0.1% v/v Tween20, pH 7.4), then duplicate wells for each animal incubated with 0, 0.25, 0.5, 1, 2, 3, 4 and 5 M potassium thiocyanate solution for 10 min at room temperature. Plates were washed a further six times with PBST, then residual antibody binding detected according to the standard ELISA protocol. The absorbance readings from wells with no potassium thiocyanate represented total antibody binding and absorbance readings in the presence of increasing concentrations of potassium thiocyanate were converted to a percentage of total binding. Data were fitted to a graph of log~10~ molar concentration of potassium thiocyanate versus normalised response by non-linear regression to estimate half maximal inhibitory concentration (IC~50~) values.

2.6. Statistical analyses {#s0040}
-------------------------

A generalised additive mixed modelling (GAMM) approach was undertaken for analysis of longitudinal FEC data from each trial. The models were fitted by restricted maximum likelihood (REML) to log(FWEC + 1), considering an identify link function and Gaussian residuals, with treatment group (either vaccinated or control) as the fixed effect and animal identity as a random effect. Separate smoothing splines for each group were used to fit their longitudinal pattern, while allowing for heterogeneous variances between groups and a temporal autoregressive correlation structure. The longitudinal FEC data were summarised for graphical representation using the median as a statistical measure of central tendency which is robust to outlying observations. cFEC and worm burden data were analysed using negative binomial generalised linear models with a logarithmic link function accounting for data over-dispersion as described previously ([@b0060]). The data generated across trials were aggregated for a meta-analysis of cFEC and worm burden by integrating the random effects of the individual trials into an overall negative binomial generalised linear mixed model (NB GLMM) with treatment group as a fixed effect. For analysis of relationships between antibody avidity and reduction in cFEC, correlation analyses were performed using Spearman's rank-order correlation. The serum antibody level was modelled using linear mixed models (LMMs) fitted by REML to rank-based inverse normal transformed data, including treatment group and time point as fixed effects and animal identity as a random effect. Post-hoc pair-wise comparisons were conducted from the LMM results, with the corresponding *P* values adjusted for the false discovery rate. Post-mortem mucosal antibody levels were modelled by fitting a one-way ANOVA model to rank-based inverse normal transformed data. Statistical test significance was assessed at the usual 5% significance level.

3. Results {#s0045}
==========

3.1. Guiding vaccine refinement -- vaccine efficacy in Trials 1--5 {#s0050}
------------------------------------------------------------------

In each trial in which lambs were immunised with the eight-antigen vaccine ([Table 1](#t0005){ref-type="table"}), the median FEC of immunised lambs across the time course demonstrated repeatable, although variable, vaccine efficacy ([Fig. 1](#f0005){ref-type="fig"}). In 85% of lambs in Trials 1--5, immunisation resulted in a reduced mean cFEC compared with that of control lambs in the same trial ([Fig. 2](#f0010){ref-type="fig"}A). Variable efficacy was observed within each trial ([Fig. 2](#f0010){ref-type="fig"}B) and this variability, together with the antibody analyses, was a key factor in undertaking simplification of the vaccine. The meta-analysis testing for differences between the cFECs of vaccinated (eight-antigen vaccine) and control animals across the five vaccine trials demonstrated an overall statistically significant effect of vaccination on cFEC reduction (*P* = 0.009) and the meta-analysis testing for differences between these groups across the five vaccine trials demonstrated an overall statistically significant effect of vaccination on worm burden reduction (*P* \< 0.0001).Fig. 1Effects of immunisation of lambs with an eight-antigen cocktail from *Teladorsagia circumcincta* on faecal egg counts across the time course of infection after larval challenge. Each panel represents a separate trial and shows median faecal egg count (with interquartile range) for groups of lambs challenged with 2000 *T. circumcincta* three times per week for 4 weeks following immunisation with an eight-protein cocktail in the context of Quil A (dashed line, open circles) or with Quil A alone (solid line, closed circles). Each data point represents the median FEC derived from observations on 7, 14^\*^, 12, 16, 16 and 12 lambs in Trials 1, 2, 3, 4a, 4b and 5 respectively. ^\*^In Trial 2, a cohort of seven lambs was euthanased at day 84, so from day 84 to day 112 each data point represents the median FEC of the remaining seven lambs.Fig. 2Effect of an eight-antigen cocktail derived from *Teladorsagia circumcincta* on cumulative faecal egg count of lambs after challenge infection. To allow comparison across different trials, efficacy is presented as % reduction in cumulative faecal egg count, calculated as follows: % cFEC reduction = \[1 − (cFECv/mean cFECc)\] × 100 where cFECv = cFEC for an individual vaccinated animal in that trial and cFECc = mean cFEC for the control animals in the same trial. Each data point on each panel represents a single vaccinate. (A) All data from all trials plotted together. (B) Data from individual trials plotted separately.

3.2. Guiding vaccine refinement - antibody responses in Trials 1--5 {#s0055}
-------------------------------------------------------------------

Immunisation of lambs with the eight-antigen vaccine (Group 1 in all trials) resulted in increased antigen-specific serum IgG and IgA in each trial. This reflected the levels and profile of antibody responses to these antigens observed in the initial two trials ([@b0060]). Trial 5 data are shown in [Supplementary Fig. S1](#s0080){ref-type="sec"} as an example. In abomasal mucus of immunised lambs in each trial for which immunoglobulin levels were assessed (Trials 1, 2, 3 and 5), average levels of Tci-APY-1- and Tci-MEP-1-specific IgG and IgA were higher than for any other recombinant protein (Trial 5 data are shown in [Supplementary Fig. S1](#s0080){ref-type="sec"} as an example).

Control group (Group 2 in all trials) lambs in Trials 1, 2, 3 and 5, which had received injections of adjuvant prior to parasite challenge, had increased Tci-APY-1- and Tci-MEP-1-specific IgG and IgA in their sera after challenge in each trial (Trial 5 data are shown in [Supplementary Fig. S2](#s0080){ref-type="sec"} as an example), whereas no consistent increases in antigen-specific IgG in control lambs were observed for any other recombinant protein tested. In the abomasal mucus of controls in each trial, average Tci-APY-1- and Tci-MEP-1-specific IgG and IgA levels were higher compared with levels of these antibodies against the other six recombinant proteins (Trial 5 data are shown in [Supplementary Fig. S2](#s0080){ref-type="sec"} as an example). The two exceptions to this were: in Trial 3, levels of Tci-ES20-specific IgA were similar to those of Tci-APY-1-specific IgA and, in Trial 2, levels of Tci-SAA-1-specific IgG were similar to those of Tci-APY-1-specific IgG (data not shown).

Investigations of the relationship of antigen-specific antibody avidity with vaccine efficacy focussed on serum IgG, IgG1 and IgG2 in animals immunised with the eight-antigen vaccine (Group 1 in all trials) collected 2 weeks after the final immunisation in Trials 1--5. The analysis incorporated all lambs protected by immunisation, as determined by having a positive value for the percentage of reduction in cFEC (i.e. each animal represented by a point above the X axis in [Fig. 2](#f0010){ref-type="fig"}B). For total serum IgG, a statistically significant positive correlation between the percentage of reduction in cFEC and antibody avidity was only observed for Tci-APY-1 (*r*~s~ = 0.30; *P* = 0.019). Subclass-specific analyses demonstrated statistically significant positive correlations between the percentage of reduction in cFEC and IgG1 (*r*~s~ = 0.28; *P* = 0.030), but not IgG2, avidity for Tci-APY-1 ([Fig. 3](#f0015){ref-type="fig"}). Based on these outcomes from the analysis of Trials 1--5, a trial (Trial 6) using a simplified prototype containing Tci-APY-1 and Tci-MEP-1 or mTci-APY-1 (i.e. the loss of function mutant for Tci-APY-1) and Tci-MEP-1 was performed ([Table 1](#t0005){ref-type="table"}).Fig. 3The relationship between antibody avidity and efficacy of an eight-antigen cocktail derived from *Teladorsagia circumcincta* on lamb cumulative faecal egg counts after challenge infection. Avidity of the interaction between total IgG (A), IgG1 (B) and IgG2 (C) and the antigen *T. circumcincta* apyrase-1 (Tci-APY-1) was expressed as a half maximal inhibitory concentration (IC50) value, defined as the concentration of potassium thiocyanate required to reduce the maximal response (in the absence of potassium thiocyanate) by 50%, and plotted against efficacy (presented as % reduction in cumulative faecal egg count). The 95% confidence bands of the best fit line are shown and each graph is annotated with the estimated correlation (*r*~s~) between the biological parameters together with the associated *P* value.

3.3. Efficacy of the simplified vaccine -- Trial 6 {#s0060}
--------------------------------------------------

Lambs in all groups began to excrete *T. circumcincta* eggs from 16-19 days after the start of challenge ([Fig. 4](#f0020){ref-type="fig"}A). At peak egg shedding (day 82), the mean FEC in the eight-antigen vaccine recipients (Group 1) was 135 ± 44 eggs per gram (EPG), and in the controls (Group 2), the mean FEC was 304 ± 75 EPG. At the same time point, the mean FEC in the two-antigen vaccine group (Group 3; Tci-APY-1 plus Tci-MEP-1) was 342 ± 90 EPG, whereas in lambs that received mTci-APY-1 and Tci-MEP-1 (Group 4), the mean FEC was 186 ± 45 EPG ([Table 2](#t0010){ref-type="table"}). The GAMM analysis identified statistically significant differences in patterns of mean FEC between the groups over the time course of the experiment (*P* = 0.044); in particular, the mean FEC of the eight-antigen recipients (Group 1) was significantly lower than that of the control (adjuvant only) group (*P* = 0.013), and the difference between the mean FEC of the mTci-APY-1 and Tci-MEP-1 recipients (Group 4) and the controls approached statistical significance (*P* = 0.093). Mean cumulative FEC levels ([Fig. 4](#f0020){ref-type="fig"}B; [Table 2](#t0010){ref-type="table"}) were reduced by 43% in Group 4 (mTci-APY-1 plus Tci-MEP-1) compared with the controls (*P* = 0.079), but only by 3% in lambs immunised with Tci-APY-1 and Tci-MEP-1 (Group 3).Fig. 4Effects of the eight- and two-protein recombinant vaccines against *Teladorsagia circumcincta* on lamb faecal egg counts during and after challenge infection in Trial 6. The mean values for faecal egg counts over the period of the experiment are depicted in A (±S.E.M.) whereas in B, the cumulative faecal egg counts for each lamb, calculated at the end of the experiment, are shown, together with the mean ± S.E.M. In each group *n* = 10, with the exception of the "All 8 antigens" group where *n* = 9.Table 2The effect of the eight- and two-protein recombinant vaccines against *Teladorsagia circumcincta* on faecal egg counts during challenge infection and worm burdens measured at the end of the experiment.GroupPeak egg output (FEC on Day 82, eggs per gram)[a](#tblfn3){ref-type="table-fn"}% Reduction in peak egg output relative to controlCumulative FEC at post mortem (eggs per gram)[a](#tblfn3){ref-type="table-fn"}% Reduction in cumulative FEC relative to controlGroup 1: 8-antigen vaccine135 ± 4466%4616 ± 1332\
(*P* = 0.288)[b](#tblfn4){ref-type="table-fn"}30%Group 2: Control, adjuvant only304 ± 75--6573 ± 1093--Group 3: Tci-APY-1 plus Tci-MEP-1342 ± 90−12.5%6371 ± 1264\
(*P* = 0.923)3%Group 4: mTci-APY-1 plus Tci-MEP-1186 ± 4539%3721 ± 526\
(*P* = 0.079)43%[^4][^5]

Abomasal nematode burdens at post-mortem are shown in [Fig. 5](#f0025){ref-type="fig"}. The mean worm count in each of the groups of immunised lambs was lower than that of the controls (34--52% average reduction in worm count). Worm burdens in the immunised groups in Trial 6 were not statistically significant in comparison with each other, or with those of the control group. When the data from lambs immunised with the eight-antigen vaccine in Trial 6 were incorporated with those from all previous trials and the meta-analyses testing for differences between the cFECs and worm burdens of vaccinated and control animals across all six vaccine trials was re-performed, overall statistically significant effects of vaccination (*P* = 0.006) on cFEC reduction and worm burden reduction (*P* \< 0.0001) were observed.Fig. 5Effect of the eight- and two-protein recombinant vaccines against *Teladorsagia circumcincta* on lamb abomasal worm burden after larval challenge in Trial 6. The nematode counts for each lamb are shown, together with the mean ± S.E.M. In each group *n* = 10, with the exception of the "All 8 antigens" group where *n* = 9.

Antigen-specific serum and mucosal antibody levels were similar to those observed in the previous trials ([Supplementary Figs. S3 and S4](#s0080){ref-type="sec"}). Serum levels of Tci-APY-1-specific IgG were statistically significantly (*P* = 0.002) elevated in sera taken 3 weeks after the final (third) immunisation) in lambs immunised with mTci-APY-1 plus Tci-MEP-1 compared with the other immunised and control groups ([Supplementary Fig. S3](#s0080){ref-type="sec"}C). At post-mortem, levels of Tci-APY-1-specific mucosal IgG were statistically significantly (*P* = 0.026) elevated in lambs immunised with all eight antigens compared with those immunised with Tci-APY-1 plus Tci-MEP-1 ([Supplementary Fig. S4](#s0080){ref-type="sec"}A). There were no other statistically significant differences between levels of serum or mucosal IgG and IgA against Tci-APY-1 or Tci-MEP-1 or IgG avidity for Tci-APY-1 in any of the groups of vaccinates in this trial.

4. Discussion {#s0065}
=============

We demonstrated repeated efficacy of a prototype recombinant vaccine for *T. circumcincta*; however, notable variability between trials and between animals within trials was observed. We exploited this variability between and within trials as a tool to target the most effective antigens in the cocktail to simplify the vaccine.

The relationship between the percentage of reduction in cFEC and IgG avidity in vaccinated sheep for one antigen, Tci-APY-1, and its increased recognition by IgG and IgA in control sheep following a trickle challenge, indicated that this antigen should be considered for inclusion in a simplified prototype. In previous studies ([@b0060], [@b0065]), we used recombinant Tci-APY-1 as an active enzyme in the vaccine cocktail and the recombinant Tci-APY-1 efficiently hydrolysed the purinergic nucleotide ATP in vitro to give an indication that it retained some of the tertiary structure of native apyrase. However, a recent publication ([@b0125]) addressing adjuvancy in vaccine preparations demonstrated that transient ATP release at the injection site is required for optimal efficacy of some adjuvants and that co-injection of mice with an adjuvanted influenza vaccine plus active apyrase led to inhibition of innate and adaptive responses to the vaccine compared with injection in the absence of apyrase ([@b0125]). For this reason, in Trial 6, a vaccine was formulated with mTci-APY-1 using a mutagenesis strategy previously used with an apyrase from humans to produce a loss-of-function mutant enzyme with folding properties identical to the wild type version ([@b0025]). This approach, of using inactive versions of recombinant parasite-derived immunomodulators, has been shown to enhance efficacy of a recombinant vaccine composed of two immunomodulatory molecules (abundant larval transcript-1 (LsALT) and cysteine proteinase inhibitor-2 (LsCPI)) when used in mice against the filarial nematode, *Litomosoides sigmodontis*, with increased efficacy in mice immunised with functionally-inactivated LsALT and LcCPI being associated with enhancement of Th-2 responses (production of parasite-specific IgG1) and enhanced parasite antigen presentation by dendritic cells ([@b0010]). In Trial 6 in the work described here, lambs immunised with mTci-APY-1 and Tci-MEP-1 (Group 4) demonstrated a substantially lower mean FEC at peak egg shedding and a lower cFEC throughout the trial than those immunised with the non-mutated Tci-APY-1 and Tci-MEP-1 (Group 3) or the eight-antigen vaccine, suggesting an enhanced effect of the vaccine when the apyrase was non-functional. Mean antigen-specific levels of serum IgG against Tci-APY-1 were also higher in Group 4 lambs 2 weeks after final immunisation than in Group 3 lambs ([Supplementary Fig. S3](#s0080){ref-type="sec"}C), although cellular responses were not recorded.

In Trial 6, Group 4 lambs exhibited reductions in both mean FEC and worm burden, whereas Group 3 animals exhibited only reductions in mean worm burden. The relationship between *T. circumcincta* burden and FEC is not straightforward or linear ([@b0105]) and is it has been demonstrated that there is a strong density-dependent effect of parasite numbers on worm fecundity ([@b0015]). The relationship between FEC and worm burden is further complicated in experiments such as the ones described here where FEC is recorded longitudinally at various time points across the trial, whereas worm burden is a static measurement estimated post-mortem only. However, if the desired outcome of vaccination is to prevent parasite transmission through reduced pasture contamination, the impact of the vaccine on worm egg shedding must be considered as the most important parameter. The eight-antigen vaccine and the mTci-APY-1-containing vaccine here were able to suppress FEC but, as with most other vaccines against parasitic nematodes (reviewed in [@b0020]), levels of suppression required for the vaccine to have a significant impact on lamb production have not yet been established. The threshold for protection will be dependent on many aspects of the management system including husbandry, climate, and how the development of natural immunity is impacted by reduced exposure levels ([@b0080]); we are currently acquiring baseline field data in a range of management systems to inform models for determining the required vaccine efficacy.

The mTci-APY-1 plus Tci-MEP-1 vaccine reduced both cFEC and worm burden, with the caveat that inherent variability in FEC and worm burden, even with accurately measured doses of infective larvae, makes statistical interpretation of the data challenging ([@b0105]). The meta-analyses performed here clearly illustrate this variability. In the NB GLMM analyses of the effects of vaccination on cFEC across all trials, predicted mean cFECs are attributed to both the control and vaccinated groups as part of the analytical process and the S.E.M. for both groups is high, representing ±27% of the mean values. The reason for variability between and within trials is under investigation using a variety of analytical, modelling and empirical approaches, but FEC is clearly affected by the establishment rate of the infection and is, thereafter, regulated by a number of host-specific factors ([@b0045]). The key factors identified by [@b0030] as being associated with establishment rate in naïve lambs were host breed and age, infective dose, method of dose administration and the number of repeated infective doses. Of these factors, those relating to administration of infective larvae were standardised across trials here and host breed was as similar as possible when using a commercial cross-breed in trials spanning 7 years. With the exception of Trial 4a, where 3 month old lambs were used, the age of the lambs was similar across trials, but variability in FEC in both the control and vaccinated groups (see [Fig. 2](#f0010){ref-type="fig"}B) was high irrespective of lamb age. The sex ratios in the groups of lambs may contribute to variation in FEC, with castrated 1--5 month old male blackface lambs shown previously to have significantly higher worm egg counts than female lambs of the same age ([@b0005]). For this reason, all groups were balanced in each trial for numbers of male and female lambs, although there was little indication in these trials of differences in FEC between male and female Texel cross lambs (data not shown).

Overall, in Trial 6, the dual antigen prototype vaccine containing mTci-APY-1 and Tci-MEP-1 performed as well as, if not better than, the proven eight-antigen vaccine in terms of reducing mean cFEC and worm burden, suggesting that further exploitation of this combination of antigens may yield an effective, simplified vaccine. The required efficacy of such a vaccine will be examined through further experimental and modelling studies.

Appendix A. Supplementary data {#s0080}
==============================

The following are the Supplementary data to this article:Supplementary Fig. S1Antibody responses of sheep to the recombinant proteins used to immunise Group 1 (vaccinated sheep) in Trial 5. Each data point represents the mean value derived from 12 sheep. (A and B) Serum antibody responses for vaccinated sheep. (A) IgG; (B) IgA. (C and D) Abomasal mucosal antibody responses for vaccinated sheep at post-mortem. (C) IgG; (D) IgA.

Supplementary Fig. S2Antibody responses of Group 2 (Control) sheep to the recombinant proteins used in Trial 5. Each data point represents the mean value derived from 12 sheep. (A and B) Serum antibody responses for control sheep. (A) IgG; (B) IgA. (C and D) Abomasal mucosal antibody responses (±S.E.M.) for these sheep at post-mortem. (C) IgG; (D) IgA.

Supplementary Fig. S3Antibody responses of sheep to the recombinant proteins used in Trial 6. Each data point represents the mean value derived from nine sheep (A and B) or 10 sheep (C-F). (A and B) Serum antibody responses for sheep immunised with eight antigens. (A) IgG; (B) IgA. (C and D) Serum antibody responses for sheep in each group against wild type Tci-APY-1 (C and D) and Tci-MEP-1 (E and F). (C and E) Mean IgG levels (± S.E.M.). (D and F) Mean IgA levels (± S.E.M.).

Supplementary Fig. S4Mucosal antibody responses of sheep, at post-mortem, to the recombinant proteins used in Trial 6. Each data point represents the mean value (± S.E.M.) derived from nine sheep (eight-antigen group) or 10 sheep (all other groups). (A and B) Mean mucosal IgG and IgA levels, respectively, against wild-type *T. circumcincta* apyrase-1 (Tci-APY-1). (C and D) Mean mucosal IgG and IgA levels, respectively, against Tci-MEP-1.
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[^1]: These authors contributed equally to this work.

[^2]: *n* = 14 until day 84 of experiment, seven thereafter.

[^3]: In the eight-antigen recipient groups in each trial, a single lamb was removed from the experiment due to unrelated health issues; thus, the number of replicates in Group 1 in these trials is one fewer than in the control groups.

[^4]: Mean ± S.E.M., *n* = 10 for each group with the exception of Group 1 where *n* = 9.

[^5]: Compared with Group 2 (Control, adjuvant only).
